COV-AID Trial: Effect of Anti-Interleukin Drugs in COVID-19

COV-AID Trial: Effect of Anti-Interleukin Drugs in COVID-19
share Share

The coronavirus infection continues to cause significant morbidity and mortality. COVID-19 is a new illness, and clinicians are still trying to find the most effective treatment strategies. Interleukin (IL)-1 and IL-6 blockade have been proposed as one possible option. However, study results so far are conflicting.


COV-AID, a prospective, multicentre, open-label, randomised controlled trial, was conducted to study whether the blockade of IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure and signs of systemic cytokine release syndrome. Sixteen hospitals in Belgium participated in the study. Study patients had a proven diagnosis of COVID-19 with symptoms between 6 and 16 days, a PaO2:FiO2 of less than 350 mm Hg on room air or less than 280 mm Hg on supplemental oxygen, and signs of a cytokine release syndrome in their serum.


During the first randomisation, patients were assigned to receive subcutaneous anakinra once daily (100 mg) for 28 days or until discharge, or no IL-1 blockade. During the second randomisation, patients received a single dose of siltuximab intravenously, or a single dose of tocilizumab intravenously, or no IL-6 blockade.


The primary outcome of the study was the time to clinical improvement, defined as the time from randomisation to an increase in at least two points on a 6-category ordinal scale or to discharge from the hospital alive. Safety was also assessed.


Findings show that the median time to clinical improvement was 12 days in the IL-1 blockade group versus 12 days in the no IL-1 blockage group. The estimated median time to clinical improvement in the IL-6 blockade group was 11 days versus 12 days in the no IL-6 blockage group. A total of 55 patients died during the study, but there was no significant difference in mortality between the treatment groups. Serious adverse events and serious infections were also similar across the study groups.


These findings suggest that drugs targeting IL-1 or IL-6 did not shorten the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, low SOFA score and low baseline mortality risk.


Source: The Lancet

Image Credit: iStock


«« Impact of Treatment Variability on ARDS Mortality

Respiratory Subphenotypes of COVID-19-Related ARDS »»


Declercq J et al. (2021) Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. The Lancet Respiratory Medicine.

Published on : Tue, 2 Nov 2021

Related Articles

COVID-19 pneumonia is an evolving disease. In this review, the authors focus on the development of its pathophysiologic characteristics... Read more

There is panic around the globe as news of a new variant of coronavirus circulated this week. The variant is believed to harbour... Read more

A major challenge in ICUs even before the COVID-19 pandemic was ventilator-associated pneumonia (VAP). However, now that the... Read more

hypoxia, respiratory failure, COVID-19, Interleukin-6, interleukin 1, anti-interleukin drugs COV-AID Trial: Effect of Anti-Interleukin Drugs in COVID-19

No comment

Please login to leave a comment...

Highlighted Products